Envoy Medical Reports Director/Officer Changes & Compensatory Info

TL;DR

Envoy Medical (COCH) filed an 8-K detailing director/officer changes and compensation. Watch for updates.

AI Summary

Envoy Medical, Inc. filed an 8-K on June 11, 2024, reporting events as of June 6, 2024. The filing includes information regarding the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also covers Regulation FD disclosures and financial statements and exhibits.

Why It Matters

Changes in a company's board and executive officers, along with details on their compensation, can signal shifts in strategy or governance that may impact investors.

Risk Assessment

Risk Level: medium — Changes in key personnel and compensation arrangements can indicate internal shifts that may affect the company's future performance and strategic direction.

Key Players & Entities

• Envoy Medical, Inc. (company) — Registrant
• COCH (company) — Ticker Symbol
• June 6, 2024 (date) — Earliest event reported
• June 11, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share COCH The Nasdaq Stock Mar
• $11.50 — A Common Stock at an exercise price of $11.50 per share COCHW The Nasdaq Stock Ma
• $40,000 — nual cash compensation in the amount of $40,000, and, in connection with his appointmen

Filing Documents

• ea0207623-8k_envoy.htm (8-K) — 32KB
• ea020762301ex99-1_envoy.htm (EX-99.1) — 18KB
• 0001213900-24-051511.txt ( ) — 271KB
• coch-20240606.xsd (EX-101.SCH) — 4KB
• coch-20240606_def.xml (EX-101.DEF) — 26KB
• coch-20240606_lab.xml (EX-101.LAB) — 36KB
• coch-20240606_pre.xml (EX-101.PRE) — 25KB
• ea0207623-8k_envoy_htm.xml (XML) — 6KB

02 Departure of Directors or Certain Officers; Election of

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Resignation On June 6, 2024, Dr. Whitney Haring-Smith, notified the Company of his decision to resign from the board of directors of the Company (the "Board") effective immediately. Dr. Haring-Smith did not resign from the Board because of a disagreement with the Company on any matter relating to the Company's operations, policies or practices. Director Appointment On June 7, 2024, the Board appointed Michael Crowe to fill the vacancy created by Dr. Haring-Smith's resignation. Mr. Crowe has decades of experience in the medical device industry with a focus on operations. Since March 2023, Mr. Crowe has served as Senior Vice President Operations for Bioventus LLC. Previously, he served as Vice President Operations for Abbott Vascular from January 2015 to March 2023. Mr. Crowe earlier served in similar roles for Caris Life Sciences, Covidien Devices, Johnson & Johnson, Iomega Corporation, and SKF USA, Inc. Mr. Crowe earned a bachelor's degree in engineering from the University of Louisville and an MBA from Duke University. There are no arrangements or understandings between Mr. Crowe and any other person pursuant to which he was selected as a director, and there are no transactions in which he has an interest requiring disclosure under Item 404(a) of Regulation S-K. Mr. Crowe will participate in the standard fee arrangements for non-executive directors, which are described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under the heading "Non-Employee Director Compensation," filed with the Securities and Exchange Commission on April 1, 2024. Under the existing director compensation arrangements, Mr. Crowe will be entitled to annual cash compensation in the amount of $40,000, and, in connection with his appointment to the Board, Mr. Crowe will be granted a sto

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 11, 2024, the Company issued a press release announcing the resignation of Dr. Haring-Smith and appointment of Mr. Crowe to the Board. A copy of the press release is attached hereto as Exhibit 99.1 to this report and is incorporated in this Item 7.01 by reference. The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under theSecurities Act of 1933, as amended, or theExchange Act, except as expressly provided by specific reference in such a filing. Item9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release Dated June 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENVOY MEDICAL, INC. June 11, 2024 By: /s/ David R. Wells David R. Wells Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR